The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksShire Share News (SHP)

  • There is currently no data for SHP

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Shire gets approval for hereditary angioedema treatment in Japan

Fri, 21st Sep 2018 07:19

(Sharecast News) - Rare disease specialist Shire announced on Friday that the Ministry of Health, Labour and Welfare (MHLW) in Japan has granted manufacturing and marketing authorisation for its 'FIRAZYR' icatibant injection, for the acute treatment of hereditary angioedema (HAE) attacks in adult patients with HAE.The FTSE 100 drugmaker described HAE as a "rare genetic disease", characterised by recurrent attacks of localised oedema.It said the areas of the body most commonly affected were the extremities, skin and gastrointestinal tract, adding that less frequently, HAE could cause life-threatening attacks due to obstruction in the upper airways.Symptoms of HAE often presented in childhood, and while attacks could occur at any age, Shire said early onset could predict a more severe disease course."As a long-term partner to the HAE community, we continually strive to bring treatments to those living with HAE around the world," said Shire's executive vice-president and head of research and development Andreas Busch."HAE attacks can be unpredictable and debilitating and we are delighted that, subject to price listing, we will be able to provide the Japanese HAE community with the first subcutaneous on-demand therapy to treat acute HAE attacks."Shire said that for most people, attacks of HAE were caused by a deficiency of a protein called C1-esterase-inhibitor (C1-INH) - either there was not enough of it, or it did not function properly.Without sufficient or functional C1-INH, plasma kallikrein in the body was not appropriately controlled, it explained.Overactive plasma kallikrein led to excessive release of bradykinin, which caused blood vessels to release fluid, leading to the swelling which characterises HAE.Shire said FIRAZYR worked by blocking bradykinin from binding to certain receptors in the body, thereby treating the symptoms of acute attacks of HAE.The use of FIRAZYR in Japanese patients was examined in an open-label, single-arm, Phase 3 study of eight adult patients with a confirmed diagnosis of HAE who experienced angioedema attacks.During the study, three patients self-administered FIRAZYR and five patients had FIRAZYR administered by a physician.The primary efficacy endpoint was time to onset of symptom relief (TOSR), defined as a 50% reduction from baseline in patient visual analogue scale (VAS) score."The study showed that FIRAZYR was well tolerated and demonstrated symptom relief during an acute HAE attack through a single injection," the Shire board said in its statement."Overall, median TOSR was 1.75 hours, and TOSR was similar for patients who self-administered FIRAZYR or who had FIRAZYR administered by a physician."Symptom relief was attained as early as one hour after FIRAZYR injection and all patients had symptom relief within five hours."The most common adverse events in patients treated with FIRAZYR were injection site reactions such as erythema, or swelling, which were found to be mild to moderate in severity.
More News
30 Nov 2018 07:38

LONDON MARKET PRE-OPEN: Ecolab To Acquire Bioquell For GBP141 Million

LONDON (Alliance News) - Stock prices in London are seen opening marginally lower on Friday as investors await a meeting of US and Chinese leaders at the G20 summit.IG futures indicate the FTSE is

Read more
30 Nov 2018 07:23

Shire gets EC approval for hereditary angioedema jab

(Sharecast News) - Shire's injectable treatment for hereditary angioedema (HAE) has been cleared for launch in European, having enjoyed early success in the US.

Read more
28 Nov 2018 07:53

Shire's Lanadelumab Help Study Meets Primary And Secondary Endpoints

LONDON (Alliance News) - Shire PLC said Tuesday it has published the full results of its phase III Help study of its hereditary angioedema drug Lanadelumab showing that the study met all of its is

Read more
20 Nov 2018 14:34

EU clears Takeda's Shire acquisition on divestment condition

(Sharecast News) - The European Commission has cleared Takeda Pharmaceutical's £46bn acquisition of Shire, subject to the divestment of a bowel disease drug under development by Shire.

Read more
1 Nov 2018 12:48

TOP NEWS: Shire Revenue Climbs On Strong Performance From Immunology

LONDON (Alliance News) - Shire PLC on Thursday updated its guidance and said its revenue grew in the third quarter of of 2018 as a result of strong Immunology division growth, recent product and a

Read more
1 Nov 2018 12:09

Shire sales remain solid, Takeda deal 'on track'

(Sharecast News) - Shire Pharmaceuticals, the subject of a $62bn takeover by Japan's Takeda, said its focus on rare diseases had offset foreign exchange weakness and boosted third-quarter profits.

Read more
1 Nov 2018 08:48

LONDON MARKET OPEN: Oil Stocks And Strong Pound Weigh On FTSE 100

LONDON (Alliance News) - Stocks in London opened mixed on Thursday, with heavyweight oil majors and a stronger pound hampering the FTSE 100, ahead of the Bank of England's interest rate decion

Read more
31 Oct 2018 06:11

Takeda's raises full-year outlook after Q2 profit rise

TOKYO, Oct 31 (Reuters) - Takeda Pharmaceutical Co Ltd on Wednesday raised its annual operating profit outlook to 268.9 billion yen. That compares with an earlier company estimate of yen an

Read more
29 Oct 2018 12:19

Takeda proposes selling off Shire drug to gain merger clearance

(Sharecast News) - Takeda Pharmaceuticals may need to sell off one of Shire's pipeline drugs in order to gain European regulatory clearance for the agreed $62bn takeover.

Read more
29 Oct 2018 12:19

Takeda proposes selling off Shire drug to gain merger clearance

(Sharecast News) - Takeda Pharmaceuticals may need to sell off one of Shire's pipeline drugs in order to gain European regulatory clearance for the agreed $62bn takeover.

Read more
29 Oct 2018 10:51

WINNERS & LOSERS SUMMARY: HSBC Rises After Upbeat Third Quarter

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Monday.----------FTSE 100 - WINNERS----------HSBC,

Read more
29 Oct 2018 07:35

LONDON MARKET PRE-OPEN: Better-Than-Expected HSBC To Lift FTSE 100

LONDON (Alliance News) - Stocks in London are set to open on firmer ground on Monday, following last week's sell-off, while traders eye Chancellor Philip Hammond's UK government shares in in

Read more
26 Oct 2018 07:52

Takeda Secures JPY1 Trillion Of Financing To Help Shire Deal

LONDON (Alliance News) - Japan's Takeda Pharmaceuticals Inc on Friday said it has secured new financing to help it with its acquisition of FTSE 100 member Shire PLC.The new short-term a

Read more
25 Oct 2018 16:21

Shire hopes to get green light for US Flexbumin manufacture

(Sharecast News) - Shire on Thursday filed a submission to the US food and drug administration to gain approval to manufacture Flexbumin at its new facility in the state of Georgia.

Read more
25 Oct 2018 16:03

UK Earnings, Trading Statements Calendar - Next 7 Days

Friday 26 October GlencoreQ3 ProductionInternational Consolidated Airlines GroupQ3 Bank 1

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.